Phase II trial of SAR439859 vs endocrine monotherapy in pre- and post-menopausal, estrogen receptor-positive (ER plus )/human epidermal growth factor receptor 2-negative (HER2-), locally advanced or metastatic breast cancer (BC) with prior exposure to hormonal therapies.

dc.authorwosidBetancourt, Rafael/JCP-1922-2023
dc.authorwosidliu, liu/JEO-6900-2023
dc.authorwosidcong, z/KCF-0053-2024
dc.contributor.authorTolaney, Sara M.
dc.contributor.authorCicin, Irfan
dc.contributor.authorBetancourt, Rafael
dc.contributor.authorChan, Arlene
dc.contributor.authorKaen, Diego
dc.contributor.authorKaufman, Peter A.
dc.contributor.authorDelaloge, Suzette
dc.date.accessioned2024-06-12T11:23:58Z
dc.date.available2024-06-12T11:23:58Z
dc.date.issued2020
dc.departmentTrakya Üniversitesien_US
dc.descriptionAnnual Meeting of the American-Society-of-Clinical-Oncology (ASCO) -- MAY 29-31, 2020 -- ELECTR NETWORKen_US
dc.description.abstract[Abstract Not Available]en_US
dc.description.sponsorshipAmer Soc Clin Oncolen_US
dc.description.sponsorshipSanofien_US
dc.description.sponsorshipSanofien_US
dc.identifier.issn0732-183X
dc.identifier.issn1527-7755
dc.identifier.issue15en_US
dc.identifier.urihttps://hdl.handle.net/20.500.14551/26746
dc.identifier.volume38en_US
dc.identifier.wosWOS:000560368309024en_US
dc.identifier.wosqualityQ1en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.language.isoenen_US
dc.publisherLippincott Williams & Wilkinsen_US
dc.relation.ispartofJournal Of Clinical Oncologyen_US
dc.relation.publicationcategoryKonferans Öğesi - Uluslararası - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subject[No Keywords]en_US
dc.titlePhase II trial of SAR439859 vs endocrine monotherapy in pre- and post-menopausal, estrogen receptor-positive (ER plus )/human epidermal growth factor receptor 2-negative (HER2-), locally advanced or metastatic breast cancer (BC) with prior exposure to hormonal therapies.en_US
dc.typeConference Objecten_US

Dosyalar